Avalo Therapeutics's 15min chart shows expanding Bollinger Bands and a bullish Marubozu.

Avalo Therapeutics' 15-minute chart has exhibited a bullish trend, with the Bollinger Bands expanding upward and a bullish Marubozu formation on August 22, 2025, at 12:30. This indicates that the market is being driven by strong buying interest, with buyers firmly in control. Consequently, it is likely that the bullish momentum will persist.

Avalo Therapeutics' 15-minute chart has exhibited a bullish trend, with the Bollinger Bands expanding upward and a bullish Marubozu formation on August 22, 2025, at 12:30. This indicates that the market is being driven by strong buying interest, with buyers firmly in control. Consequently, it is likely that the bullish momentum will persist.

According to National Research's 15-minute chart analysis, a KDJ Golden Cross and Bullish Marubozu signal was triggered on August 21, 2025, at 13:45. This technical indicator combination suggests a shift in momentum towards the upside, indicating potential further price increases. The dominance of buyers in the market is likely to continue, supporting a bullish trend [1].

The KDJ Golden Cross occurs when the K line of the KDJ indicator crosses above the D line, signaling a potential shift in the stock's momentum towards the upside. The Bullish Marubozu candlestick pattern, characterized by a long body with no shadows above or below, suggests that the stock is being driven by strong buying pressure. These signals follow a broader trend of narrowing Bollinger Bands and KDJ Death Cross formations observed in several other stocks, including ASGN and Cushing NextGen [2, 3].

Technical analysis provides valuable insights into potential stock price movements, but it is crucial for investors to consider these signals in conjunction with fundamental analysis and broader market conditions. As of July 7, 2025, several notable companies have seen updates to their analyst ratings and price targets, reflecting the evolving opinions of financial experts. Positive Outlook: Alnylam Pharma (ALNY) received a "Buy" rating from Jefferies with a price target of $384.00 [1]. Chime Financial (CHYM) was initiated with an "Overweight" rating by multiple firms, including Morgan Stanley and Barclays, with targets ranging from $39.00 to $40.00 [1]. CryoPort (CYRX) was rated "Buy" by BTIG Research with a price target of $10.00 [1]. Datadog (DDOG) had its price target raised from $150.00 to $175.00 by Bank of America, reiterating a "Buy" rating [1]. Energy Transfer (ET) was initiated with a "Buy" rating by TD Cowen with a price target of $22.00 [1]. Grab (GRAB) was rated "Buy" by Jefferies with a price target of $5.70, indicating a 20.94% upside [1]. Home Depot (HD) was rated "Buy" by TD Cowen with a price target of $470.00 [1]. Intuit (INTU) was rated "Buy" by Morgan Stanley with a price target of $900.00 [1]. JPMorgan Chase & Co. (JPM) had a $298.00 target set by Evercore ISI with an "Outperform" rating [1]. Kinder Morgan (KMI) was initiated with a "Buy" rating by TD Cowen [1]. Lam Research (LRCX) had its "Buy" rating reiterated by Citigroup [1]. MACOM Technology Solutions (MTSI) had its target raised from $136.00 to $154.00 by Truist Financial, maintaining a "Buy" rating [1]. Monopar Therapeutics (MNPR) was initiated with an "Overweight" rating by Cantor Fitzgerald and a target of $74.00 [1]. Norwegian Cruise Line (NCLH) received a "Buy" rating from Jefferies with a price target of $29.00 [1]. Oracle (ORCL) received a "Buy" rating from UBS with a $250.00 target [1]. Oportun Financial (OPRT) was rated "Buy" at B. Riley Financial with an $11.00 price target [1]. Ovintiv (OVV) was rated "Buy" at Barclays Capital with a price target of $55.00 [1]. Phibro Animal Health (PAHC) was upgraded at JPMorgan Chase from Neutral to Overweight, with the price target raised from $25.00 to $35.00 [1]. Progressive (PGR) was downgraded by Morgan Stanley from Overweight to Equal Weight, with a price target of $290.00 [1]. Pulse Biosciences (PLSE) was initiated by Oppenheimer with an "Outperform" rating and a $22.00 price target [1]. PTC (PTC) had its Overweight rating reiterated by KeyCorp Bank [1]. Rockwell Automation (ROK) was initiated by CICC Research with a "Buy" rating and a price target of $320.00 [1].

Analysts consider Avalo Therapeutics a speculative buy ahead of the LOTUS trial results. Cantor Fitzgerald has initiated coverage of Avalo Therapeutics (NASDAQ: AVTX) with an Overweight rating, highlighting the potential of the company's lead asset, AVTX-009. The biotechnology company, based in Maryland, focuses on the treatment of immune dysregulation, with AVTX-009 being a humanized monoclonal antibody targeting interleukin-1β (IL-1β) in hidradenitis suppurativa, an inflammatory skin condition [2].

Investors should keep an eye on the two technical levels in major indexes, as indicated by Bank of America. If the S&P 500 drops below 6,200, it could indicate a more serious decline in store for the market. Conversely, if the Dow rises above 45,000, that could be a sign of a bullish breakout. The market rally needs more breadth to continue, and investors should monitor these levels closely [3].

References:
[1] https://www.ainvest.com/news/chart-industries-triggers-kdj-golden-cross-bullish-momentum-builds-marubozu-candle-2508-55/
[2] https://www.ainvest.com/news/avalo-therapeutics-speculative-buy-avtx-009-lotus-results-2508-23/
[3] https://www.businessinsider.com/stock-market-outlook-sp500-dow-technical-analysis-sell-off-rally-2025-8